Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ian Walters"'
Autor:
Josep M. Llovet, Riccardo Lencioni, Jean-Luc Raoul, Valérie Boige, Ho Yeong Lim, Charissa Chang, Masatoshi Kudo, Joong-Won Park, Ian Walters, Yoon-Koo Kang, Eric Assenat, Ferran Torres, José Ríos, Thomas Decaens, Robert Montal
Publikováno v:
Journal of Hepatology
Journal of Hepatology, 2017, 66 (6), pp.1166-1172. ⟨10.1016/j.jhep.2017.01.012⟩
Recercat. Dipósit de la Recerca de Catalunya
instname
Journal of Hepatology, Elsevier, 2017, 66 (6), pp.1166-1172. ⟨10.1016/j.jhep.2017.01.012⟩
Dipòsit Digital de la UB
Universidad de Barcelona
Journal of Hepatology, 2017, 66 (6), pp.1166-1172. ⟨10.1016/j.jhep.2017.01.012⟩
Recercat. Dipósit de la Recerca de Catalunya
instname
Journal of Hepatology, Elsevier, 2017, 66 (6), pp.1166-1172. ⟨10.1016/j.jhep.2017.01.012⟩
Dipòsit Digital de la UB
Universidad de Barcelona
Background & Aims: The Modified Response Evaluation Criteria in Solid Tumors (mRECIST) was developed to overcome the limitations of standard RECIST criteria in response assessment of hepatocellular carcinoma (HCC). We aimed to investigate whether obj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dc51def091d1e0e8afb3bbd202650b8
https://hal.umontpellier.fr/hal-01790263
https://hal.umontpellier.fr/hal-01790263
Autor:
Jay Easaw, Derek J. Jonker, Ian Walters, Jenny Shannon, Jeremy Shapiro, Siobhan Ng, Lillian L. Siu, John Zalcberg, Christopher J. O'Callaghan, Andrew Strickland, Thierry Alcindor, Rami Kotb, Malcolm J. Moore, Heather Jane Au, Fabyolla El-Tahche, Sabe Sabesan, Mark Jeffery, Muhammad Salim, Jolie Ringash, Dongsheng Tu
Publikováno v:
Cancer. 120(2)
BACKGROUND The CO.20 trial randomized patients with K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer to receive cetuximab (CET) plus brivanib alaninate (BRIV) or CET plus placebo (CET/placebo). METHODS Quality of life (QoL) was
Autor:
Andrew Haydon, Louise M. Nott, Timothy J. Price, John Simes, Michael B. Sawyer, Danielle Charpentier, Malcolm J. Moore, Derek J. Jonker, Jeremy Shapiro, Nadine M Magoski, Jehan Siddiqui, Christos S. Karapetis, Michael Jefford, Lillian L. Siu, John Zalcberg, Ian Walters, Christopher J. O'Callaghan, Winston Liauw, Félix Couture, Dongsheng Tu
Publikováno v:
Journal of Clinical Oncology. 30:3504-3504
3504 Background: The anti-EGFR monoclonal antibody CET has improved survival in pts with chemotherapy refractory, K-RAS WT mCRC. BRIV is a potent inhibitor of multiple receptor tyrosine kinases including both VEGFR and FGFR. The combination of CET an
Autor:
Andrew Strickland, Christopher J. O'Callaghan, Fabyolla El-Tahche, Jennifer Shannon, Derek J. Jonker, Heather-Jane Au, Lillian L. Siu, Jeremy Shapiro, Muhammad Salim, Ian Walters, Malcolm J. Moore, Rami Kotb, John Zalcberg, Mark Jeffery, Dongsheng Tu, Jacob C. Easaw, Jolie Ringash, Sabe Sabesan, Siobhan Ng, Thierry Alcindor
Publikováno v:
Journal of Clinical Oncology. 30:542-542
542 Background: The CO.20 trial randomized pts with K-RAS WT chemotherapy refractory mCRC to receive CET + BRIV (Arm A) or CET + placebo (Arm B). Although overall survival (primary endpoint) was not significantly improved (HR=0.88, p=0.12) in this he